QTTB Q32 Bio Inc. - Common Stock
$15,38
Kurs · Aug 18, 2026
Fundamentaldaten per Aug 5, 2026
52W-Spanne
$2–$24
63% of range
Analystenbewertung
BUY
11 analysts
Kursziel
$43
+178% upside
P/E (TTM)
6.4
ROE
200.3%
Nettogewinnmarge
55.5%
QTTB Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$15.38
Marktkapitalisierung
$198M
P/E (TTM)
6.4
EPS (TTM)
$2.42
Umsatz (TTM)
$54M
Dividendenrendite
—
ROE
200.3%
Verschuldungsgrad
—
52W-Spanne
$2 – $24
QTTB Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$54M
2018-12-31
→
2025-12-31
EPS
$2.42
2021-12-31
→
2025-12-31
Freier Cashflow
$-34M
2018-12-31
→
2025-12-31
Margen
55.5%
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
QTTB
Peer-Median
P/E (TTM)
6.4
16.6
P/S (TTM) (K/V (TTM))
3.7
9.4
P/B (K/B)
4.7
2.4
Price / FCF (Kurs / FCF)
-5.9
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
QTTB
Peer-Median
Operating Margin (Betriebsgewinnmarge)
31.4%
—
Net Profit Margin (Nettogewinnmarge)
55.5%
-298.0%
ROA
38.7%
-38.4%
ROE
200.3%
-63.7%
ROIC
40.2%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
QTTB
Peer-Median
Current Ratio (Liquiditätsgrad)
4.9
3.9
Quick Ratio
4.3
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
QTTB
Peer-Median
Revenue CAGR 3Y (Umsatz CAGR 3J)
155.9%
—
Revenue CAGR 5Y (Umsatz CAGR 5J)
81.8%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
QTTB
Peer-Median
QTTB Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
11 Analysten
- Starker Kauf 3 27,3%
- Kauf 7 63,6%
- Halten 1 9,1%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
4 Analysten · 2026-08-18
Median
$38.00
Mittelwert
$42.75
← Unter allen Zielen
$15.38
Tief
$36.00
Hoch
$59.00
Median-Ziel
$38.00
+147,0%
Mittelwert-Ziel
$42.75
+177,9%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
1.00%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $-0.44 | $-0.55 | 0.11% |
| 31. März 2026 | $-0.54 | $-0.69 | 0.15% |
| 31. Dezember 2025 | $3.65 | $-0.88 | 4.5% |
| 30. September 2025 | $-0.60 | $-1.21 | 0.61% |
| 30. Juni 2025 | $-0.78 | $-1.00 | 0.22% |
| 31. März 2025 | $-0.90 | $-1.25 | 0.35% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| QTTB | $43M | 1.4 | — | 55.5% | 200.3% | — |
| ZURA | — | — | — | — | — | — |
| EVMN | $540M | -1.5 | 85.7% | -529.8% | -401.2% | — |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | — |
| MPLT | $773M | -0.9 | — | — | -151.1% | — |
| CABA | $220M | -1.0 | — | — | -115.5% | — |
| OCGN | $422M | -5.6 | 8.8% | -1537.4% | 1488.8% | — |
| LRMR | $317M | -2.2 | — | — | -167.4% | — |
| PBYI | $300M | 9.8 | -0.91% | 13.6% | 26.5% | — |
| RZLT | $388M | -4.6 | — | — | -56.9% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| R&D Expense | $19M | $48M | $32M | $98M | $93M | $100M | $89M | $48M | |
| SG&A Expense | $18M | $18M | $10M | $38M | $37M | $33M | $22M | $17M | |
| Operating Expenses | $37M | $66M | $42M | $136M | $130M | $133M | $112M | $65M | |
| Operating Income | $17M | $-66M | $-48M | $-133M | $-96M | $-130M | $-110M | $-60M | |
| Other Non-op | $1M | $4M | $1M | $134M | $185.0K | $2M | $6M | $4M | |
| Pretax Income | $30M | $-46M | $-53M | $1M | $-96M | · | · | · | |
| Income Tax | $0 | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 | $0 | |
| Net Income | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| EPS (Basic) | $2.42 | $-5.12 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| EPS (Diluted) | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 | · | · | · | |
| Shares (Basic) | 12,300,568 | 9,320,884 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| Shares (Diluted) | 12,314,796 | 9,657,696 | 349,060 | 57,399,762 | 55,283,318 | · | · | · | |
| EBITDA | $17M | $-66M | · | $-133M | $-96M | $-130M | $-110M | $-62M |
Bilanz 23
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $78M | $26M | $34M | $108M | $217M | $54M | $38M | |
| Short-term Investments | · | $0 | $0 | $141M | · | · | · | · | |
| Prepaid Expense | $7M | $4M | $3M | $6M | $7M | $2M | $4M | $7M | |
| Other Current Assets | $20.0K | $396.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $55M | $82M | $29M | $181M | $192M | $220M | $267M | $222M | |
| PP&E (Net) | $979.0K | $1M | $2M | $1M | $2M | $37M | $43M | $36M | |
| PP&E (Gross) | $3M | $3M | $3M | $7M | $8M | $53M | $51M | $38M | |
| Accum. Depreciation | $2M | $1M | $966.0K | $6M | $6M | $16M | $8M | $2M | |
| Other Non-current Assets | $0 | $116.0K | $5M | · | · | · | · | · | |
| Total Assets | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Accounts Payable | $879.0K | $3M | $3M | $1M | $2M | $5M | $3M | $16M | |
| Accrued Liabilities | $4M | $7M | $10M | · | · | · | · | · | |
| Current Liabilities | $11M | $16M | $14M | $23M | $17M | $23M | $12M | $23M | |
| Capital Leases | $5M | $6M | $6M | $28M | $24M | $13M | · | · | |
| Other Non-current Liabilities | $0 | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $20M | $87M | $119M | $50M | $42M | $68M | $52M | $63M | |
| Common Stock | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $5.0K | $4.0K | $3.0K | |
| Paid-in Capital | $247M | $240M | $4M | $608M | · | · | · | · | |
| Retained Earnings | $-205M | $-235M | $-187M | $-429M | $-424M | $-328M | $-200M | $-96M | |
| AOCI | · | $0 | $0 | $-404.0K | $-7.0K | $0 | $183.0K | $-77.0K | |
| Stockholders' Equity | $42M | $6M | $-183M | $-131M | $170M | $196M | $259M | $196M | |
| Liabilities + Equity | $62M | $92M | $47M | $228M | $212M | $264M | $311M | $259M | |
| Shares Outstanding | 12,858,047 | 12,197,615 | 359,569 | 57,483,910 | 57,150,274 | 50,265,575 | 45,116,742 | 37,358,526 |
Cashflow 11
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $5M | $4M | $1M | $13M | $17M | $13M | $8M | $3M | |
| Deferred Tax | · | $100.0K | $300.0K | · | · | · | · | · | |
| Restructuring | · | · | $10M | · | · | · | · | · | |
| Operating Cash Flow | $-34M | $-68M | $-19M | $-114M | $-110M | $-94M | $-91M | $-43M | |
| CapEx | $0 | $75.0K | $5.0K | $1M | $2M | $4M | $22M | $25M | |
| Investing Cash Flow | $7M | $20M | $-5.0K | $37M | $-51M | $205M | $-52M | $-122M | |
| Stock Issued | $0 | $42M | $0 | $0 | $50M | · | $135M | · | |
| Net Stock Activity | $0 | $42M | · | $0 | $50M | · | $135M | · | |
| Financing Cash Flow | $-3M | $95M | $406.0K | $596.0K | $52M | $53M | $158M | $151M | |
| Net Change in Cash | · | · | $5M | $-76M | $-108M | $164M | $15M | $-13M | |
| Free Cash Flow | $-34M | $-68M | · | $-115M | $-112M | $-98M | $-113M | $-68M |
Rentabilität 7
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| Net Margin | 55.5% | · | · | -156.0% | -281.9% | -4762.9% | -6237.4% | -1553.1% | |
| Pretax Margin | 55.5% | · | · | 37.3% | · | · | · | · | |
| EBITDA Margin | 31.4% | · | · | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1671.1% | |
| ROA | 38.7% | -68.5% | · | -2.3% | -40.3% | -44.8% | -36.5% | -28.8% | |
| ROE | 200.3% | -398.3% | · | -2.6% | -52.0% | -70.3% | -40.2% | -28.0% | |
| ROIC | 40.2% | -1165.3% | · | -30.2% | · | · | · | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.0 | · | 8.0 | 11.1 | 9.7 | 21.5 | 8.7 | |
| Quick Ratio | 4.3 | 4.7 | · | 1.5 | 6.3 | 9.6 | 4.3 | 1.5 |
Effizienz 1
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.0 | · | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 |
Wachstumsraten 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | · | · | · | -90.6% | 1157.2% | · | · | · | |
| Revenue CAGR 3Y | 155.9% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 81.8% | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $54M | $0 | $-7M | $3M | $34M | $3M | $2M | $5M | |
| Net Income TTM | $30M | $-48M | $-54M | $-5M | $-96M | $-129M | $-104M | $-56M | |
| Market Cap | $43M | $42M | · | $1.30B | $3.74B | $10.21B | $16.81B | $15.04B | |
| P/E | 1.4 | -0.5 | -0.1 | -252.0 | -37.9 | · | · | · | |
| P/S | 0.8 | · | · | 406.4 | 110.2 | 3780.5 | 10090.3 | 2825.3 | |
| P/B | 1.0 | 7.4 | · | 7.3 | 22.1 | 52.1 | 65.0 | 77.2 | |
| P / Tangible Book | 1.0 | 7.4 | · | · | 22.1 | 52.1 | · | · | |
| P / Cash Flow | -1.3 | -0.6 | · | -11.5 | -34.1 | -108.3 | -184.0 | -353.3 | |
| P / FCF | -1.3 | -0.6 | · | -11.3 | -33.4 | -104.2 | -148.5 | -222.8 | |
| Earnings Yield | 72.9% | -191.3% | -1406.8% | -0.40% | -2.6% | · | · | · |
Gewinn- und Verlustrechnung 14
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-15M | $2M | $3M | $3M | $802.0K | $802.0K | |
| R&D Expense | $4M | $3M | $3M | $4M | $5M | $7M | $11M | $14M | $13M | $10M | $8M | $7M | $8M | $8M | $27M | $26M | |
| SG&A Expense | $5M | $5M | $5M | $4M | $4M | $5M | $4M | $4M | $5M | $5M | $3M | $2M | $2M | $2M | $8M | $8M | |
| Operating Expenses | $9M | $8M | $8M | $8M | $9M | $12M | $15M | $19M | $18M | $15M | $11M | $10M | $10M | $10M | $35M | $34M | |
| Operating Income | $-9M | $-8M | $46M | $-8M | $-9M | $-12M | $-15M | $-19M | $-18M | $-15M | $-26M | $-8M | $-7M | $-7M | $-34M | $-33M | |
| Other Non-op | $319.0K | $113.0K | $115.0K | $188.0K | $-318.0K | $1M | $358.0K | $1M | $2M | $158.0K | $196.0K | $84.0K | $165.0K | $578.0K | $1M | $1M | |
| Pretax Income | · | · | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-16M | $1M | $-27M | $-14M | $-6M | $-7M | $-33M | $-32M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $21.0K | $0 | $0 | $0 | $383.0K | $-65.0K | $0 | $0 | $-403.0K | $46.0K | |
| Net Income | $-9M | $-8M | $58M | $-7M | $-9M | $-11M | $-14M | $-18M | $-17M | $1M | $-27M | $-14M | $-6M | $-7M | $-34M | $-34M | |
| EPS (Basic) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $-3.27 | $-1.46 | $-1.42 | $1.03 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.60 | $-0.59 | |
| EPS (Diluted) | $-0.44 | $-0.54 | $4.70 | $-0.60 | $-0.78 | $-0.90 | $2.63 | $-1.46 | $-1.42 | $-6.33 | $-76.91 | $-40.52 | $-16.69 | $-19.84 | $-0.58 | $-0.59 | |
| Shares (Basic) | 20,342,345 | 14,095,371 | -24,335,204 | 12,240,542 | 12,197,615 | 12,197,615 | -15,715,032 | 12,076,412 | 11,964,224 | 995,280 | -689,787 | 346,288 | 347,936 | 344,623 | -114,712,971 | 57,447,192 | |
| Shares (Diluted) | 20,342,345 | 14,095,371 | -24,320,976 | 12,240,542 | 12,197,615 | 12,197,615 | -16,717,120 | 12,076,412 | 11,964,224 | 2,334,180 | -689,787 | 346,288 | 347,936 | 344,623 | -115,308,584 | 57,447,192 | |
| EBITDA | $-9M | $-8M | · | $-8M | $-9M | $-12M | · | $-19M | $-18M | $-15M | · | $-31M | $-31M | $-28M | · | $-33M |
Bilanz 23
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $106M | $51M | $48M | $49M | $55M | $65M | $78M | $89M | $98M | $116M | $26M | $29M | $77M | $39M | $34M | $43M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | · | · | $0 | $74M | $50M | $111M | · | · | |
| Prepaid Expense | $3M | $6M | $7M | $2M | $3M | $3M | $4M | $5M | $4M | $3M | $3M | $3M | $4M | $4M | $6M | $12M | |
| Other Current Assets | $19.0K | $20.0K | $20.0K | $24.0K | $77.0K | $93.0K | $396.0K | $229.0K | $51.0K | $67.0K | $83.0K | · | · | · | · | · | |
| Current Assets | $110M | $57M | $55M | $51M | $58M | $69M | $82M | $94M | $112M | $138M | $29M | $107M | $131M | $154M | $181M | $213M | |
| PP&E (Net) | $804.0K | $889.0K | $979.0K | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $0 | $845.0K | $1M | $1M | $1M | |
| PP&E (Gross) | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $0 | $7M | $7M | $7M | $8M | |
| Accum. Depreciation | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $966.0K | $0 | $7M | $6M | $6M | $7M | |
| Other Non-current Assets | · | · | $0 | $0 | $570.0K | $444.0K | $116.0K | $40.0K | $1M | $1M | $5M | · | · | · | · | · | |
| Total Assets | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Accounts Payable | $2M | $653.0K | $879.0K | $973.0K | $910.0K | $3M | $3M | $1M | $2M | $5M | $3M | $8M | $3M | $4M | $1M | $5M | |
| Accrued Liabilities | $4M | $4M | $4M | $4M | $4M | $5M | $7M | $9M | $11M | $20M | $10M | · | · | · | · | · | |
| Current Liabilities | $5M | $11M | $11M | $11M | $12M | $15M | $16M | $14M | $17M | $33M | $14M | $25M | $23M | $19M | $23M | $25M | |
| Capital Leases | $5M | $5M | $5M | $5M | $5M | $5M | $6M | $6M | $6M | $6M | $6M | $27M | $27M | $27M | $28M | $28M | |
| Other Non-current Liabilities | · | · | $0 | $55M | $55M | $55M | $55M | $55M | $55M | $55M | $55M | · | · | · | · | · | |
| Total Liabilities | $10M | $17M | $20M | $76M | $78M | $83M | $87M | $86M | $91M | $104M | $119M | $52M | $50M | $46M | $50M | $54M | |
| Common Stock | $3.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $1.0K | $6.0K | $6.0K | $6.0K | $6.0K | $6.0K | |
| Paid-in Capital | $327M | $259M | $247M | $244M | $243M | $242M | $240M | $239M | $237M | $235M | $4M | $614M | $612M | $610M | · | · | |
| Retained Earnings | $-222M | $-213M | $-205M | $-263M | $-255M | $-246M | $-235M | $-221M | $-203M | $-186M | $-187M | $-526M | $-493M | $-458M | $-429M | $-395M | |
| AOCI | · | · | · | $0 | $0 | $0 | · | $-1.0K | $-1.0K | $-5.0K | $0 | $-36.0K | $-88.0K | $-182.0K | $-404.0K | $-457.0K | |
| Stockholders' Equity | $106M | $46M | $42M | $-18M | $-12M | $-4M | $6M | $18M | $34M | $49M | $-183M | $88M | $119M | $152M | $178M | $209M | |
| Liabilities + Equity | $116M | $64M | $62M | $58M | $66M | $79M | $92M | $105M | $124M | $152M | $47M | $140M | $169M | $198M | $228M | $263M | |
| Shares Outstanding | 23,736,600 | 14,629,463 | 12,858,047 | 12,304,352 | 12,197,615 | 12,197,615 | 12,197,615 | 12,138,869 | 11,995,206 | 11,929,520 | 359,569 | 57,902,210 | 57,798,133 | 57,794,767 | 57,483,910 | 57,480,610 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $417.0K | $521.0K | $-4M | $-2M | $296.0K | $3M | $3M | |
| Restructuring | · | · | · | $0 | $0 | $900.0K | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-3M | $-6M | $-6M | $-4M | $-11M | $-12M | $-11M | $-20M | $-22M | $-15M | $-11M | $42M | $2M | $-12M | $-27M | $-25M | |
| CapEx | · | · | $0 | $0 | · | · | $2.0K | $58.0K | $15.0K | $0 | $0 | $-223.0K | $-224.0K | $5.0K | $9.0K | $6.0K | |
| Investing Cash Flow | $0 | $0 | $7M | $0 | $0 | $0 | $-2.0K | $10M | $10M | $97.0K | $0 | $-92M | $-31M | $-5.0K | $18M | $-108M | |
| Stock Issued | $0 | $10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $42M | $0 | $0 | $0 | $0 | · | · | |
| Net Stock Activity | · | $10M | · | · | · | $0 | · | · | · | $42M | · | · | · | · | · | · | |
| Financing Cash Flow | $59M | $9M | $-2M | $-2M | · | · | $317.0K | $997.0K | $-6M | $99M | $76.0K | $178.0K | $-120.0K | $15.0K | $32.0K | $124.0K | |
| Net Change in Cash | · | · | · | · | · | · | · | · | · | · | · | $-48M | $37M | $5M | $-9M | $-133M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-15M | · | · | · | $-26M | · | · |
Rentabilität 7
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| Net Margin | 3636.6% | 3963.0% | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -9899.4% | -3596.5% | · | -4205.2% | |
| Pretax Margin | · | · | · | 3358.6% | 3341.2% | 2973.3% | · | · | · | · | · | · | -8278.2% | -3247.1% | · | -3939.3% | |
| EBITDA Margin | 3706.5% | 4021.9% | · | 3444.1% | 3229.2% | 3296.0% | · | · | · | · | · | · | -8705.1% | -3430.3% | · | -4097.5% | |
| ROA | -9.8% | -10.7% | · | -9.1% | -10.0% | -9.5% | · | -14.4% | -11.6% | 0.59% | · | -16.4% | -15.4% | -11.3% | · | -13.7% | |
| ROE | -19.1% | -36.0% | · | 9658.8% | -89.2% | -49.3% | · | -33.0% | -22.2% | 1.0% | · | -22.2% | -19.5% | -13.8% | · | -16.6% | |
| ROIC | · | · | · | 41.1% | 75.0% | 304.6% | · | -102.8% | -53.5% | -30.4% | · | -35.1% | -25.8% | -18.1% | · | -15.7% |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.3 | 5.4 | · | 4.6 | 5.1 | 4.7 | · | 6.5 | 6.5 | 4.2 | · | 4.2 | 5.7 | 8.3 | · | 8.4 | |
| Quick Ratio | 19.7 | 4.8 | · | 4.4 | 4.8 | 4.5 | · | 6.2 | 5.7 | 3.5 | · | 4.1 | 5.5 | 8.1 | · | 1.7 |
Effizienz 1
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | -0.0 | -0.0 | · | -0.0 | -0.0 | -0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $2M | · | $2M | $2M | $2M | · | $2M | $5M | $8M | · | $9M | $8M | $5M | · | $4M | |
| Net Income TTM | $-33M | $-36M | · | $-46M | $-55M | $-45M | · | $-48M | $-36M | $-26M | · | $-60M | $-75M | $22M | · | $-1M | |
| Market Cap | $302M | $94M | · | $24M | $18M | $20M | · | $542M | $215M | $203M | · | $1.22B | $921M | $1.07B | · | $1.67B | |
| P/E | -5.4 | -2.3 | · | -0.5 | -0.3 | -0.2 | · | -0.9 | -0.3 | -0.2 | · | -0.3 | -0.4 | -1.0 | · | -579.6 | |
| P/S | 162.7 | 50.5 | · | 13.1 | 9.8 | 10.8 | · | 291.4 | 42.5 | 25.4 | · | 138.4 | 118.7 | 200.2 | · | 408.0 | |
| P/B | 2.9 | 2.0 | · | -1.3 | -1.5 | -5.0 | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Tangible Book | 2.9 | 2.0 | · | · | · | · | · | 29.6 | 6.4 | 4.2 | · | 13.8 | 7.7 | 7.1 | · | 8.0 | |
| P / Cash Flow | · | -14.8 | · | · | · | -1.6 | · | · | · | -14.0 | · | · | · | -41.1 | · | · | |
| P / FCF | · | · | · | · | · | · | · | · | · | -14.0 | · | · | · | -40.8 | · | · | |
| Earnings Yield | -18.5% | -43.9% | · | -188.9% | -306.0% | -612.7% | · | -111.5% | -361.9% | -489.3% | · | -368.7% | -236.2% | -104.4% | · | -0.17% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $54M | $0 | $-7M | $3M | $34M |
| Betriebsgewinnmarge % | 31.4% | — | — | -4154.6% | -282.4% |
| Nettoergebnis | $30M | $-48M | $-54M | $-5M | $-96M |
| Verwässerte EPS | $2.42 | $-6.58 | $-153.96 | $-0.09 | $-1.73 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 4.9 | 5.0 | — | 8.0 | 11.1 |
| Quick Ratio | 4.3 | 4.7 | — | 1.5 | 6.3 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $-34M | $-68M | — | $-115M | $-112M |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 77 Einreicher · $280.5M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 33 (+25 vs. Vorquartal) | 8 (0 vs. Vorquartal) | 14 (+1 vs. Vorquartal) | 14 (+4 vs. Vorquartal) | +13.3M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | $52.590.554 | 4.127.987 | 18,75% | Aktien |
| Boxer Capital Management, LLC | $40.122.209 | 3.149.310 | 14,30% | Aktien |
| Atlas Venture Life Science Advisors, LLC | $34.615.930 | 2.717.106 | 12,34% | Aktien |
| BVF INC/IL | $29.939.000 | 2.350.000 | 10,67% | Aktien |
| RA CAPITAL MANAGEMENT, L.P. | $29.715.502 | 2.332.457 | 10,59% | Aktien |
| Point72 Asset Management, L.P. | $14.949.065 | 1.173.396 | 5,33% | Aktien |
| Opaleye Management Inc. | $11.860.940 | 931.000 | 4,23% | Aktien |
| Logos Global Management LP | $10.192.000 | 800.000 | 3,63% | Aktien |
| SummitTX Capital, L.P. | $9.348.281 | 733.774 | 3,33% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $6.609.550 | 518.803 | 2,36% | Aktien |
| Ikarian Capital, LLC | $5.478.200 | 430.000 | 1,95% | Aktien |
| Woodline Partners LP | $3.646.341 | 286.212 | 1,30% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $3.474.860 | 272.752 | 1,24% | Aktien |
| Sanofi | $3.109.617 | 244.083 | 1,11% | Aktien |
| ACORN CAPITAL ADVISORS, LLC | $2.754.019 | 216.171 | 0,98% | Aktien |
| Ikarian Capital, LLC | $2.548.000 | 200.000 | 0,91% | Verkaufsoption |
| RENAISSANCE TECHNOLOGIES LLC | $2.288.104 | 179.600 | 0,82% | Aktien |
| JANE STREET GROUP, LLC | $1.686.164 | 132.352 | 0,60% | Aktien |
| MONIMUS CAPITAL MANAGEMENT, LP | $1.682.139 | 132.036 | 0,60% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $1.661.640 | 130.427 | 0,59% | Aktien |
| CITADEL ADVISORS LLC | $1.537.247 | 120.663 | 0,55% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $1.273.455 | 99.923 | 0,45% | Aktien |
| MARSHALL WACE, LLP | $854.153 | 67.045 | 0,30% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $843.605 | 66.217 | 0,30% | Aktien |
| BOOTHBAY FUND MANAGEMENT, LLC | $780.962 | 61.300 | 0,28% | Verkaufsoption |
| Carlyle Group Inc. | $769.020 | 60.363 | 0,27% | Aktien |
| STATE STREET CORP | $665.206 | 52.214 | 0,24% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $631.675 | 49.582 | 0,23% | Aktien |
| Quadrature Capital Ltd | $463.685 | 36.396 | 0,17% | Aktien |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $440.970 | 34.613 | 0,16% | Aktien |
| DAFNA Capital Management LLC | $419.095 | 32.896 | 0,15% | Aktien |
| Knott David M Jr | $387.449 | 30.412 | 0,14% | Aktien |
| Affinity Asset Advisors, LLC | $353.879 | 27.777 | 0,13% | Aktien |
| Squarepoint Ops LLC | $303.085 | 23.790 | 0,11% | Aktien |
| NORTHERN TRUST CORP | $301.059 | 23.631 | 0,11% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $297.377 | 23.342 | 0,11% | Aktien |
| MANGROVE PARTNERS IM, LLC | $282.191 | 22.150 | 0,10% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $255.857 | 20.083 | 0,09% | Aktien |
| LPL Financial LLC | $231.486 | 18.170 | 0,08% | Aktien |
| UBS Group AG | $183.698 | 14.419 | 0,07% | Aktien |
| Balyasny Asset Management L.P. | $157.237 | 12.342 | 0,06% | Aktien |
| ExodusPoint Capital Management, LP | $144.421 | 11.336 | 0,05% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $139.223 | 10.928 | 0,05% | Aktien |
| XTX Topco Ltd | $138.535 | 10.874 | 0,05% | Aktien |
| Vanguard Global Advisers, LLC | $61.458 | 4.824 | 0,02% | Aktien |
| Nuveen Asset Management, LLC | $54.758 | 15.918 | 0,02% | Aktien |
| MORGAN STANLEY | $54.132 | 4.249 | 0,02% | Aktien |
| FMR LLC | $43.163 | 3.388 | 0,02% | Aktien |
| CITIGROUP INC | $36.793 | 2.888 | 0,01% | Aktien |
| BlackRock, Inc. | $25.047 | 1.966 | 0,01% | Aktien |
| Private Wealth Asset Management, LLC | $21.658 | 1.700 | 0,01% | Aktien |
| Arax Advisory Partners | $14.154 | 1.111 | 0,01% | Aktien |
| FEDERATED HERMES, INC. | $13.377 | 1.050 | 0,00% | Aktien |
| Rockefeller Capital Management L.P. | $7.351 | 577 | 0,00% | Aktien |
| JONES FINANCIAL COMPANIES LLLP | $6.585 | 500 | 0,00% | Aktien |
| VANGUARD GROUP INC | $6.358 | 1.915 | 0,00% | Aktien |
| Russell Investments Group, Ltd. | $5.784 | 454 | 0,00% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $3.860 | 303 | 0,00% | Aktien |
| EverSource Wealth Advisors, LLC | $3.058 | 240 | 0,00% | Aktien |
| ACADIAN ASSET MANAGEMENT LLC | $2.779 | 218.234 | 0,00% | Aktien |
| NISA INVESTMENT ADVISORS, LLC | $2.115 | 166 | 0,00% | Aktien |
| Truvestments Capital LLC | $2.064 | 162 | 0,00% | Aktien |
| OSAIC HOLDINGS, INC. | $1.579 | 124 | 0,00% | Aktien |
| Allworth Financial LP | $1.376 | 108 | 0,00% | Aktien |
| SBI Securities Co., Ltd. | $1.198 | 94 | 0,00% | Aktien |
| Clearstead Advisors, LLC | $854 | 67 | 0,00% | Aktien |
| Caitong International Asset Management Co., Ltd | $573 | 45 | 0,00% | Aktien |
| Federation des caisses Desjardins du Quebec | $484 | 38 | 0,00% | Aktien |
| GROUP ONE TRADING LLC | $433 | 34 | 0,00% | Aktien |
| CWM, LLC | $250 | 39 | 0,00% | Aktien |
| Cambridge Investment Research Advisors, Inc. | $230 | 18.081 | 0,00% | Aktien |
| HRT FINANCIAL LP | $203 | 15.949 | 0,00% | Aktien |
| HARBOUR INVESTMENTS, INC. | $140 | 11 | 0,00% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $25 | 2 | 0,00% | Aktien |
| AdvisorNet Financial, Inc | $25 | 2 | 0,00% | Aktien |
| DANSKE BANK A/S | $13 | 1 | 0,00% | Aktien |
| ROYAL BANK OF CANADA | $0 | 28 | 0,00% | Aktien |
Unternehmensinsider 29 Insider · 13 Führungskräfte · 18 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jodie Pope Morrison | CEO | 16. Juli 2026 A | 353.104 | 0 | 3 | $-141.391 |
| Albert Seymour | President and Chief Executive Officer | 6. September 2023 M | 150.874 | 0 | 0 | $0 |
| Lee Kalowski | CFO and President | 16. Juli 2026 A | 142.443 | 0 | 3 | $-57.038 |
| Paul Alloway | Former President and Chief Operating Officer of Homology Medicines, Inc. | 25. März 2024 S | 2.596 | 0 | 0 | $0 |
| Timothy P Kelly | Chief Operating Officer | 24. Februar 2022 A | 2.224 | 0 | 0 | $0 |
| Siyamak Rasty | Chief Operating Officer | 9. Juli 2019 S | 222.707 | 0 | 0 | $0 |
| Shelia M. Violette | Chief Scientific Officer | 16. Juli 2026 A | 130.569 | 0 | 2 | $-18.078 |
| Jason Campagna | Chief Medical Officer | 24. Februar 2025 A | 37.500 | 0 | 0 | $0 |
| Charles Michaud Jr | Former Vice President, Corporate Controller and Treasurer of Homology Medicines, Inc. | 25. März 2024 S | 927 | 0 | 0 | $0 |
| Julie Jordan | Chief Medical Officer | 3. August 2023 M | 7.496 | 0 | 0 | $0 |
| Michael Lee Blum | Chief Commercial Officer | 23. Februar 2023 A | 13.538 | 0 | 0 | $0 |
| Bradford W Smith | Chief Financial and Business Officer and Treasurer | 23. Februar 2023 A | 14.219 | 0 | 0 | $0 |
| Gabriel Cohn | Chief Medical Officer | 1. Januar 2022 M | 2.629 | 0 | 0 | $0 |
| Diyong Xu | Direktor | 12. Juni 2026 A | 625.000 | 2 | 0 | $15.000.000 |
| David S. Grayzel | Direktor | 12. Juni 2026 A | — | 0 | 0 | $0 |
| Sven Ante Lundberg | Direktor | 12. Juni 2026 A | — | 0 | 0 | $0 |
| Isaac Manke | Direktor | 12. Juni 2026 A | 53.521 | 0 | 0 | $0 |
| Arthur Tzianabos | Direktor | 12. Juni 2026 A | 7.983 | 0 | 0 | $0 |
| Mark T Iwicki | Direktor | 12. Juni 2026 A | — | 0 | 0 | $0 |
| Mary Thistle | Direktor | 12. Juni 2026 A | — | 0 | 0 | $0 |
| Kathleen Laporte | Direktor | 12. Juni 2026 A | — | 0 | 0 | $0 |
| Jeffrey V. Poulton | Direktor | 14. Juni 2023 A | — | 0 | 0 | $0 |
| Alise Reicin | Direktor | 14. Juni 2023 A | — | 0 | 0 | $0 |
| Matthew R Patterson | Direktor | 14. Juni 2023 A | — | 0 | 0 | $0 |
| Steven Gillis | Direktor | 14. Juni 2023 A | 6.068.695 | 0 | 0 | $0 |
| Kush Parmar | Direktor | 15. Juni 2022 A | 181.435 | 0 | 0 | $0 |
| Richard J. Gregory | Direktor | 15. Juni 2022 A | 10.806 | 0 | 0 | $0 |
| Cameron Wheeler | Direktor | 6. Juni 2019 A | — | 0 | 0 | $0 |
| Mahendra Shah | Direktor | 2. April 2018 A | 909.742 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 4 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP VII LLC, OrbiMed Genesis GP LLC ×5 Einreichungen | 20. Juli 2026 | 13,90% | Änderung | — | SEC |
| Atlas Venture Fund X, L.P., ATLAS VENTURE ASSOCIATES X, L.P., Atlas Venture Associates X, LLC, Atlas Venture Opportunity Fund I, L.P., Atlas Venture Associates Opportunity I, L.P., Atlas Venture Associates Opportunity I, LLC, Atlas Venture Opportunity Fund II, L.P., Atlas Venture Associates Opportunity II, L.P., Atlas Venture Associates Opportunity II, LLC, Atlas Venture Opportunity Fund Ill, L.P., Atlas Venture Associates Opportunity III, L.P., Atlas Venture Associates Opportunity III, LLC ×2 Einreichungen | 28. Mai 2026 | 3,60% | Änderung | — | SEC |
| Acorn Bioventures, L.P., Acorn Capital Advisors, GP, LLC, Anders Hove | 4. April 2024 | — | Erste Einreichung | M&A / Verkauf | SEC |
| Deerfield Mgmt III, L.P., Deerfield Private Design Fund III, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Management Company, L.P., James E. Flynn ×5 Einreichungen | 1. Mai 2020 | — | Erste Einreichung | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 8 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,70% | 10.132 SH | 8. August 2026 | Täglich |
| IWC · iShares Trust | 0,03% | 29.465 SH | 8. August 2026 | Täglich |
| AVUV · AMERICAN CENTURY ETF TRUST | 0,01% | 128.510 NS | 31. Mai 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 14.652 NS | 30. April 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 314 NS | 31. Mai 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 119.269 SH | 8. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 389.115 SH | 8. August 2026 | Täglich |
| DFSV · Dimensional ETF Trust | 0,00% | 490 NS | 30. April 2026 | N-PORT |